IOncology

Hormone receptor (HR)-positive breast cancer accounts for approximately 70% of all breast cancer cases. From the early exploration of ovarian ablation more than a century ago, to tamoxifen ushering in the era of endocrine therapy, and then to CDK4/6 inhibitor-based combinations reshaping the treatment landscape of advanced disease, each major therapeutic breakthrough has profoundly altered the survival trajectory of patients. However, treatment resistance remains a major clinical challenge. The discovery of resistance mechanisms such as PI3K/AKT/mTOR pathway alterations and ESR1 mutations has subsequently driven the development of increasingly precise targeted strategies. The 2026 Northern Breast Cancer Forum was successfully held in Qingdao from July 25 to 26. During the meeting, Oncology Frontier interviewed Prof. Yunjiang Liu from the Fourth Hospital of Hebei Medical University, who provided an in-depth overview of the major milestones in HR-positive breast cancer treatment, precision strategies following CDK4/6 inhibitor resistance, and the new opportunities created by domestically developed innovative therapies.

Recently, the China Association of Chinese Medicine (CACM) Group Standard, Integrated Evaluation of Evidence on the Efficacy of Traditional Chinese Medicine was officially released in Beijing. As the world’s first guiding standard for the integrated evaluation of evidence on the efficacy of traditional Chinese medicine (TCM), the standard was jointly developed under the leadership of Researcher Xiao Xiaohe, Professor Wang Jiabo, Academician Tian Jinzhou, Academician Chen Xiangmei, and Professor Dai Aiguo, with the participation of more than 60 leading experts from 13 universities, research institutes, medical institutions, and pharmaceutical companies across China, including the Chinese PLA General Hospital, Capital Medical University, Beijing University of Chinese Medicine, and Hunan University of Chinese Medicine.

The 3rd Yellow River Urology Congress and the 31st Academic Conference on Urology of the Shandong Medical Association were recently held, bringing together leading urologists from across China to discuss the latest advances in the field, innovations in clinical practice, talent development, and regional collaboration.

The 2026 Annual Meeting of the Chinese Urological Association (CUDA) was held in Zhengzhou from June 11–14, bringing together leading experts in urology and related disciplines under the theme "Unity, Collaboration, Innovation, and Development." The meeting focused on advancing high-quality clinical research, technological innovation, multidisciplinary collaboration (MDT), and regional cooperation, while promoting the continued development of comprehensive care for urologic diseases.

The treatment landscape for renal cell carcinoma (RCC), one of the most common malignancies of the urinary system, continues to evolve rapidly, with targeted therapy combined with immunotherapy now established as a standard first-line approach for advanced and metastatic disease. However, for patients with oligometastatic RCC, a standardized treatment strategy has yet to be established.

The 19th Chinese Urological Association (CUA) Genitourinary Oncology Conference was held in Beijing on July 3–4, 2026, under the theme "Advancing Frontiers, Standardizing Care, and Driving Collaborative Innovation." The meeting brought together leading experts in urologic oncology from across China to examine the current challenges facing the field and explore future directions for clinical research and patient care.

The 19th Chinese Urological Association (CUA) Genitourinary Oncology Conference was held in Beijing on July 3–4, 2026, bringing together leading experts from across China under the theme "Advancing Frontiers, Standardizing Care, and Driving Collaborative Innovation." The meeting provided a platform for discussing new directions in urologic oncology research and clinical practice.

The 19th Chinese Urological Association (CUA) Genitourinary Oncology Conference was successfully held in Beijing on July 3–4, 2026. Centered on the theme "Advancing Frontiers, Standardizing Care, and Driving Collaborative Innovation," the meeting featured in-depth discussions on precision oncology, early screening and prevention of prostate cancer, and the development of a robust domestic clinical research ecosystem, highlighting both the latest advances and the key challenges facing urologic oncology in China.